Roche Holding AG
RHO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 66.30 | -0.71% |
| CAC 40 | 7,924.15 | 45.54 | -0.57% |
| DAX 40 | 24,271.34 | 91.75 | -0.38% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 490.77 | 1.94% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
| NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |